Austar Lifesciences (HKG:6118) expects a net profit attributable to the owners of about 3 million yuan to 6 million yuan for the six months ended June 30, compared to a loss of about 40 million yuan in the previous year.
The company attributed the anticipated turnaround to cost-saving measures and the absence of a 32 million yuan loss from a unit incurred in the previous year.
The manufacturer and distributor of pharmaceutical equipment and consumables plan to publish their interim results later in August, according to a Tuesday filing on the Hong Kong bourse.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments